Differential Effects of Histone Deacetylases on the Expression of NKG2D Ligands and NK Cell-Mediated Anticancer Immunity in Lung Cancer Cells [PDF]
Molecules, 2021 Histone acetylation is an epigenetic mechanism that regulates the expression of various genes, such as natural killer group 2, member D (NKG2D) ligands.
Chi-Dug Kang, Kang Chi-Dug
exaly +5 more sources
NKG2D Ligands–Critical Targets for Cancer Immune Escape and Therapy [PDF]
Frontiers in Immunology, 2018 DNA damage, oncogene activation and excessive proliferation, chromatin modulations or oxidative stress are all important hallmarks of cancer. Interestingly, all of these abnormalities also induce a cellular stress response.
Ofer Mandelboim +2 more
exaly +5 more sources
Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia [PDF]
Frontiers in Immunology, 2020 CAR T cell approaches to effectively target AML and T-ALL without off-tumor effects on healthy myeloid or T cell compartments respectively are an unmet medical need.
Jérôme Ritz +2 more
exaly +5 more sources
NKG2D Ligands in Tumor Immunity: Two Sides of a Coin
Frontiers in Immunology, 2015 The activating/co-stimulatory receptor NKG2D (natural-killer group 2, member D) is expressed on the surface of all human NK, NKT, CD8+ T and subsets of γδ+ T cells.
Fahmin Basher +2 more
exaly +4 more sources
Leveraging NKG2D Ligands in Immuno-Oncology. [PDF]
Front Immunol, 2021 Immune checkpoint inhibitors (ICI) revolutionized the field of immuno-oncology and opened new avenues towards the development of novel assets to achieve durable immune control of cancer.
Fuertes MB, Domaica CI, Zwirner NW.
europepmc +2 more sources
Circular EZH2-encoded EZH2-92aa mediates immune evasion in glioblastoma via inhibition of surface NKG2D ligands. [PDF]
Nat Commun, 2022 Glioblastoma (GBM) is a highly aggressive primary brain tumour and is resistant to nearly all available treatments, including natural killer (NK) cell immunotherapy. However, the factors mediating NK cell evasion in GBM remain largely unclear.
Zhong J +12 more
europepmc +2 more sources
Mechanisms of Senescence-Related NKG2D Ligands Release and Immune Escape Induced by Chemotherapy in Neuroblastoma Cells. [PDF]
Front Cell Dev Biol, 2022 Chemotherapy-induced senescence promotes immunocyte aggregation in the tumor microenvironment by upregulating the surface expression of activating ligands in cancer cells.
Zhang Y, Hu R, Xi B, Nie D, Xu H, Liu A.
europepmc +2 more sources
A signature based on NKG2D ligands to predict the recurrence of hepatocellular carcinoma after radical resection [PDF]
Cancer Medicine, 2023 Introduction Due to the high recurrence, the HCC prognosis remains poor. Yet, the biomarkers for predicting the recurrence of high‐risk patients are currently lacking.
Dongbo Chen +8 more
doaj +2 more sources
MAPK inhibitors dynamically affect melanoma release of immune NKG2D-ligands, as soluble protein and extracellular vesicle-associated [PDF]
Frontiers in Cell and Developmental Biology, 2023 Metastatic melanoma presents, in many cases, oncogenic mutations in BRAF, a MAPK involved in proliferation of tumour cells. BRAF inhibitors, used as therapy in patients with these mutations, often lead to tumour resistance and, thus, the use of MEK ...
Silvia López-Borrego +11 more
doaj +2 more sources
Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells. [PDF]
J Immunother CancerBackground Glioblastoma (GBM) almost invariably becomes resistant towards conventional treatment of radiotherapy and temozolomide (TMZ) chemotherapy, partly due to subpopulations of intrinsically resistant glioma stem-like cells (GSC).
Baugh R +8 more
europepmc +2 more sources